|
Siga Technologies Inc (NASDAQ: SIGA) |
|
|
|
|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of Siga Technologies Inc's Business Segments
Siga Technologies Inc. is a prominent player in the field of biotechnology, particularly in the realm of biodefense and public health solutions. The company is dedicated to developing innovative products and services that protect against biological threats. Below is an extensive overview of the segments, products, and services offered by Siga Technologies Inc. showcasing their comprehensive approach to addressing critical health and safety challenges.
Segments:
1. Biodefense:
Siga Technologies Inc. places a strong emphasis on biodefense, focusing on creating countermeasures against bioterrorism and emerging infectious diseases. This segment encompasses:
- Therapeutics Development: The company is engaged in the research, development, and commercialization of therapeutics aimed at preventing and treating smallpox, a significant concern in biodefense given its potential use as a bioweapon.
- Antiviral Drug Development: Siga conducts extensive research into antiviral medications targeting a range of viral pathogens, ensuring preparedness against potential outbreaks and enhancing public health responses.
2. Health:
The health segment of Siga Technologies is committed to enhancing patient outcomes and addressing critical medical needs. Its focus includes:
- Antibiotic Development: The company has initiated the development of a variety of antibiotics aimed at treating bacterial infections, particularly those caused by multidrug-resistant organisms such as MRSA (Methicillin-resistant Staphylococcus aureus).
- Innovative Therapeutics: By focusing on unmet medical needs, Siga actively seeks to innovate in areas like infectious diseases, aiming to provide effective medical solutions for conditions that are currently challenging to treat.
3. Agrochemicals:
Siga Technologies is also involved in the agrochemical sector, focusing on sustainable agricultural solutions. This segment consists of:
- Crop Yield Enhancement: The company develops products designed to improve crop yield, which is vital for food security and agriculture sustainability.
- Environmental Impact Reduction: Sigas agrochemical innovations aim to reduce the negative environmental impact associated with traditional agricultural practices, promoting eco-friendly solutions.
Products:
1. Smallpox Drug:
- Siga Technologies flagship product is a targeted therapeutic for the treatment and prevention of smallpox. This product has received approval from the US FDA, highlighting its importance as a biodefense tool, particularly for government stockpiles against potential smallpox outbreaks.
2. Antibacterial Drugs:
- The company offers a portfolio of antibiotics that address various bacterial infections, particularly those associated with antibiotic resistance. These drugs are critical in the fight against healthcare-associated infections.
3. Antiviral Drugs:
- Siga is actively involved in the research and development of antiviral drugs that target viral pathogens, enhancing the options available for treatment of viral infections.
4. Crop Protection Products:
- Siga Technologies has developed innovative crop protection solutions, including advanced fungicides aimed at safeguarding crops against fungal infections. These products contribute to healthier crops and are essential for sustainable farming practices.
Services:
1. Research and Development:
- Siga Technologies provides comprehensive research and development services across its key sectors of biodefense, health, and agrochemicals. The companys expertise in drug discovery and biotechnology enables the delivery of customized research solutions tailored to client needs.
2. Contract Manufacturing:
- The company offers state-of-the-art contract manufacturing services, particularly geared toward government agencies and other stakeholders within the biodefense sector. This includes the production of vaccines, biologics, and other critical healthcare products, emphasizing high-quality and scalable manufacturing capabilities.
3. Consulting Services:
- Siga Technologies provides consulting services to various clients in the biodefense, health, and agrochemical arenas. These services include strategic insights on product development processes, navigating regulatory landscapes, and supporting market entry strategies.
Conclusion:
Siga Technologies Inc. represents a multifaceted organization that is deeply invested in the research and development of innovative products and solutions to combat biological threats. With a firm focus on biodefense, health, and sustainable agricultural practices, Siga continues to push the boundaries of biotechnology, ensuring that critical therapeutic and preventive measures are in place to address some of the worlds most pressing health challenges. Through a combination of advanced therapeutics, robust research capabilities, and dedicated services, Siga is well-positioned to play a crucial role in global health security and agricultural sustainability.
Composition of Siga Technologies Inc Revenues by
Segments |
| |
| Product Sales and Supportive Services |
|
 82.68 % |
of total Revenue |
| Research and Development |
|
17.32 % |
of total Revenue |
| UNITED STATES |
|
17.32 % |
of total Revenue |
| CANADA |
|
82.68 % |
of total Revenue |
| Non-US |
|
82.68 % |
of total Revenue |
Q1 three months ended (Mar 31 2025)
|
| Revenues by Business Segments |
Revenues
(in millions $) |
%
(of total Revenues) |
| Product Sales and Supportive Services |
5.82 |
82.68 % |
| Research and Development |
1.22 |
17.32 % |
| UNITED STATES |
1.22 |
17.32 % |
| CANADA |
5.82 |
82.68 % |
| Non-US |
5.82 |
82.68 % |
| Total |
7.04 |
100 % |
Q1 three months ended (Mar 31 2025)
|
| Revenue Growth rates by Segment |
Y/Y Revenue
% |
Q/Q Revenue
% |
| Product Sales and Supportive Services |
-75.62 % |
- |
| Research and Development |
-21.38 % |
- |
| UNITED STATES |
-93.01 % |
- |
| CANADA |
689.13 % |
- |
| Non-US |
-27.05 % |
- |
| Total |
-72.31 % |
-94.92 % |
Q1 three months ended (Mar 31 2025)
|
| Income by Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
-0.41 |
- |
Q1 three months ended (Mar 31 2025)
|
| Income Growth rates by Segment |
Y/Y Income
% |
Q/Q Income
% |
| Total |
- |
- |
Annual Report on Siga Technologies Inc Divisions, Sales by Country |
| |
| Product Sales and Supportive Services |
|
96.12 % |
of total Revenue |
| Research and Development |
|
3.88 % |
of total Revenue |
| UNITED STATES |
|
83.44 % |
of total Revenue |
| CANADA |
|
0.53 % |
of total Revenue |
| Non-US |
|
16.56 % |
of total Revenue |
| EMEA |
|
6.04 % |
of total Revenue |
| Asia Pacific |
|
9.99 % |
of total Revenue |
Twelve months ended 2024
|
| SIGA s Annual Revenue by Geography and Business Segments |
Sales
(in millions $) |
%
(of total Sales) |
| Product Sales and Supportive Services |
133.33 |
96.12 % |
| Research and Development |
5.39 |
3.88 % |
| UNITED STATES |
115.74 |
83.44 % |
| CANADA |
0.74 |
0.53 % |
| Non-US |
22.98 |
16.56 % |
| Total |
138.72 |
100 % |
| EMEA |
8.38 |
6.04 % |
| Asia Pacific |
13.86 |
9.99 % |
Twelve months ended 2024
|
| SIGA s Annual Income by Country and Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
59.21 |
42.69 % |
Twelve months ended 2024
|
| Annual Revenue and Income Growth by Country and Business Segments |
% Y/Y Sales Growth |
% Y/Y Income Growth |
| Product Sales and Supportive Services |
2.04 % |
- |
| Research and Development |
-41.73 % |
- |
| UNITED STATES |
-2.45 % |
- |
| Non-US |
8.03 % |
- |
| EMEA |
-58.72 % |
- |
| Asia Pacific |
1333.54 % |
- |
|
|
